The US Clarithromycin market remained under pressure during April 2026, with Clarithromycin prices declining 4% month on month due to weak seasonal pharmaceutical demand and sufficient inventory coverage among distributors and wholesalers. Reduced outpatient prescriptions for respiratory infections after the winter season significantly softened Clarithromycin spot buying activity, while intense competition among generic suppliers encouraged aggressive rebidding across the market. Stable feedstock costs and uninterrupted production schedules among major Clarithromycin exporters in India, Italy, and Spain ensured healthy product availability throughout the month. Although freight and insurance costs increased sharply, adequate import coverage and stable port conditions prevented supply shortages in the Clarithromycin market. Freight rates from East Asia to the United States rose considerably during April, increasing landed cost pressure on importers. For May 2026, the Clarithromycin market is anticipated to recover modestly by nearly 1.2% as seasonal demand gradually improves and elevated logistics expenses support firmer CFR quotations across the United States pharmaceutical sector.
